---
title: "LEA: Q2 2026 delivered higher sales, margins, and EPS, with raised full-year guidance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294498379.md"
description: "Q2 2026 saw higher sales, margins, and EPS, with strong free cash flow and significant new business awards. Full-year guidance was raised for revenue, earnings, and cash flow, despite industry production headwinds and currency volatility.Original document: Lear Corporation [LEA] Slides Release — Jul. 31 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-31T10:32:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294498379.md)
  - [en](https://longbridge.com/en/news/294498379.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294498379.md)
generator: "portal-rs"
---

# LEA: Q2 2026 delivered higher sales, margins, and EPS, with raised full-year guidance

Q2 2026 saw higher sales, margins, and EPS, with strong free cash flow and significant new business awards. Full-year guidance was raised for revenue, earnings, and cash flow, despite industry production headwinds and currency volatility.

Original document: Lear Corporation \[LEA\] Slides Release — Jul. 31 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [LEA.US](https://longbridge.com/en/quote/LEA.US.md)

## Related News & Research

- [LEA: Raised 2026 guidance after record revenue and margin gains, with strong backlog for future growth](https://longbridge.com/en/news/294535172.md)
- [Lear posts transcript of Q2 2026 earnings call](https://longbridge.com/en/news/295457907.md)
- [Walmart store workers have a new responsibility: correcting AI errors](https://longbridge.com/en/news/296213777.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**